Abstract
Background:
Decreased hemoglobin (Hb) level has been supposed to be a relatively rare side effect of a combination therapy against hepatitis C virus that consists of the NS5A inhibitor daclatasvir (DCV) and the NS3/4A protease inhibitor asunaprevir (ASV).
Methods:
The study was conducted in 75 patients with genotype 1b chronic hepatitis C virus infection who had started combination therapy with DCV and ASV at St. Marianna University School of Medicine Hospital between September 2014 and December 2014.
Results:
Among the patients examined, decreased Hb level by ≥1.5 g/dL from the values at treatment initiation was observed in 11 individuals. This was accompanied by decreased mean corpuscular volume, and iron and ferritin levels.
Conclusions:
These findings suggest that the mechanism of the phenomenon is caused by iron deficiency. The underlying mechanism and clinical impacts will need to be further examined.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Carbamates
-
Female
-
Genotype*
-
Hemoglobins / metabolism*
-
Hepacivirus / genetics*
-
Hepatitis C, Chronic / blood*
-
Hepatitis C, Chronic / drug therapy*
-
Hepatitis C, Chronic / genetics
-
Humans
-
Imidazoles* / administration & dosage
-
Imidazoles* / adverse effects
-
Iron Deficiencies*
-
Isoquinolines* / administration & dosage
-
Isoquinolines* / adverse effects
-
Male
-
Middle Aged
-
Pyrrolidines
-
Sulfonamides* / administration & dosage
-
Sulfonamides* / adverse effects
-
Valine / analogs & derivatives
Substances
-
Carbamates
-
Hemoglobins
-
Imidazoles
-
Isoquinolines
-
Pyrrolidines
-
Sulfonamides
-
Valine
-
daclatasvir
-
asunaprevir
Grants and funding
This research was partially supported by the Research Program on Hepatitis from the Japan Agency for Medical Research and Development, AMED. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.